Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
VENUS REMEDIES Mar-18 |
TEVA PHARMA Dec-13 |
VENUS REMEDIES/ TEVA PHARMA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 126 | 3,050 | - | |
Low | Rs | 61 | 2,650 | - | |
Sales per share (Unadj.) | Rs | 301.8 | 1,750.4 | - | |
Earnings per share (Unadj.) | Rs | -24.9 | 109.3 | - | |
Cash flow per share (Unadj.) | Rs | 2.5 | 250.8 | - | |
Dividends per share (Unadj.) | Rs | 0 | 95.72 | - | |
Dividend yield (eoy) | % | 0 | 3.4 | 0.0% | |
Book value per share (Unadj.) | Rs | 293.3 | 1,944.4 | - | |
Shares outstanding (eoy) | m | 12.34 | 848.00 | - | |
Bonus/Rights/Conversions | - | - | - | ||
Price / Sales ratio | x | 0.3 | 1.6 | 19.0% | |
Avg P/E ratio | x | -3.8 | 26.1 | -14.4% | |
P/CF ratio (eoy) | x | 36.7 | 11.4 | 323.4% | |
Price / Book Value ratio | x | 0.3 | 1.5 | 21.8% | |
Dividend payout | % | 0 | 87.5 | 0.0% | |
Avg Mkt Cap | Rs m | 1,154 | 2,416,571 | 0.0% | |
No. of employees | `000 | 0.9 | 44.9 | 2.1% | |
Total wages/salary | Rs m | 393 | 0 | - | |
Avg. sales/employee | Rs Th | 4,026.1 | 33,025.8 | 12.2% | |
Avg. wages/employee | Rs Th | 425.0 | 0 | - | |
Avg. net profit/employee | Rs Th | -331.8 | 2,063.1 | -16.1% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 3,724 | 1,484,344 | 0.3% | |
Other income | Rs m | 23 | 0 | - | |
Total revenues | Rs m | 3,747 | 1,484,344 | 0.3% | |
Gross profit | Rs m | 395 | 406,488 | 0.1% | |
Depreciation | Rs m | 338 | 119,981 | 0.3% | |
Interest | Rs m | 354 | 29,155 | 1.2% | |
Profit before tax | Rs m | -275 | 257,353 | -0.1% | |
Minority Interest | Rs m | 0 | 1,169 | 0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | -168,938 | 0.0% | |
Tax | Rs m | 32 | -3,142 | -1.0% | |
Profit after tax | Rs m | -307 | 92,726 | -0.3% | |
Gross profit margin | % | 10.6 | 27.4 | 38.7% | |
Effective tax rate | % | -11.5 | -1.2 | 940.2% | |
Net profit margin | % | -8.2 | 6.2 | -131.9% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 2,638 | 1,002,520 | 0.3% | |
Current liabilities | Rs m | 2,305 | 874,283 | 0.3% | |
Net working cap to sales | % | 8.9 | 8.6 | 103.5% | |
Current ratio | x | 1.1 | 1.1 | 99.8% | |
Inventory Days | Days | 135 | 91 | 149.2% | |
Debtors Days | Days | 46 | 96 | 48.3% | |
Net fixed assets | Rs m | 4,871 | 484,819 | 1.0% | |
Share capital | Rs m | 123 | 3,654 | 3.4% | |
Net worth | Rs m | 3,619 | 1,648,825 | 0.2% | |
Long term debt | Rs m | 1,374 | 758,978 | 0.2% | |
Total assets | Rs m | 7,509 | 3,392,202 | 0.2% | |
Interest coverage | x | 0.2 | 9.8 | 2.3% | |
Debt to equity ratio | x | 0.4 | 0.5 | 82.5% | |
Sales to assets ratio | x | 0.5 | 0.4 | 113.3% | |
Return on assets | % | 0.6 | 3.6 | 17.6% | |
Return on equity | % | -8.5 | 5.6 | -150.8% | |
Return on capital | % | 1.6 | 4.9 | 32.1% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 514 | 236,528 | 0.2% | |
From Investments | Rs m | -123 | -83,811 | 0.1% | |
From Financial Activity | Rs m | -387 | -283,731 | 0.1% | |
Net Cashflow | Rs m | 4 | -131,015 | -0.0% |
Compare VENUS REMEDIES With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US)
Compare VENUS REMEDIES With: AJANTA PHARMA STERLING BIOTECH NATCO PHARMA TTK HEALTHCARE AUROBINDO PHARMA
Indian share markets witnessed a sharp sell-off today and ended deep in the red.
For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.
More Views on NewsLast time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.
In this video, I'll cover your queries on intraday trading and also share my view on how to decide stop losses and target prices.
A look at what India's top equity mutual funds bought and sold in January 2021.
Do you enjoy reading Tesla and Bitcoin stories? Here's a not so famous small-cap stock to profit from the rise of EVs.
More